Bringing of PET-TDM FDG in the Determination of the Characteristics of Primary Mammary Tumors TrIple Negatives

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

132 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-05

Study Completion Date

2024-10-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

"Triple Negative" breast cancers are a heterogeneous group characterized by the absence of hormone receptors to estrogen, progesterone and the absence of expression or amplification of the HER-2 gene. This type of cancer is associated with an adverse clinical profile with a high risk of early metastatic relapse. Accurate identification of prognostic factors, as well as predictors of therapeutic response, and the contribution of targeted therapies are avenues for improving the management and survival of patients with these cancers. Such an approach requires optimal biological characterization, allowing us to understand the complexity of this group of tumors, and requires multidisciplinary collaboration in clinical trials involving anatomopathology, oncology and morpho-functional imaging.

The investigator's goal is to characterize by innovative methods (anatomo-pathological in particular Of Immunohistochemistry, and morpho-functional imaging (TEP-TDM FDG) semi-quantitative and texture) in a population of Triple Negative Breast Cancer scans better knowledge of this entity that can lead to the development of relevant therapeutic strategies and especially more adapted in the context of precision and personalized medicine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Triple Negative Breast Cancer: Identification Pilot Study of Predictive Transcriptome Profiles of Early Tumor Drug Resistance Observed in 18F-Fluorodeoxyglucose (FDG) PET

NCT02850302

Breast Neoplasms

COMPLETED NA

Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm

NCT02266420

Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm

COMPLETED NA

PET/MR Radiomics for Breast Cancer Diagnosis

NCT05466760

Breast Cancer

UNKNOWN

Contrast-enhanced Spectral Mammography (CESM) Early Quantitative Evaluation of Tumoral Response and Pathologic Complete Response Prediction for Localized Breast Cancer Treated by Neoadjuvant Chemotherapy

NCT06299202

Breast Cancer

RECRUITING NA

Triple Negative Breast Cancer: Study of Molecular and Genetic Factors

NCT01434420

Breast Cancer

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

120 consecutive patients with "Triple Negative" breast cancers operatable from the outset will be included in the study

* To assess the prognostic value of the texture parameters of PET-TDM FDG on event-free survival at 2 years.
* To assess the prognostic value of standard parameters (clinical, standard histology, conventional imaging), semi-quantitative PET-TDM FDG and innovative Immuno-histochemistry parameters for 2-year event-free survival .
* To assess correlations between continuous PET-TDM FDG texture parameters and Immuno-histochemistry.
* To assess the multivariate prognostic value of standard parameters, PET-TDM FDG imaging parameters and Immuno-histochemistry defined as relevant to 2-year event-free survival .
* Construction of an optimal prognostic nomogram combining independent parameters to isolate different prognostic subgroups.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Triple negative Breast Cancer

Triple Negative Breast Cancer operatable from the outset

TEP-TDM FDG

Intervention Type DIAGNOSTIC_TEST

Semi-quantitative PET-TDM FDG Data and Texture Analysis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TEP-TDM FDG

Semi-quantitative PET-TDM FDG Data and Texture Analysis

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with biopsy-proven triple-negative breast cancer, newly diagnosed, naïve from any treatment.
* Age - 18.
* Performance Status (PS) : 0 or 1.
* No metastasis on the extension balance.
* Treatment provided immediately by lumpectomy or mastectomy, and accepted by the patient.

Exclusion Criteria

* Severe illness or comorbidity at risk.
* A history of cancer within 5 years, with the exception of skin carcinomas (other than melanoma) or in-situ cervical carcinomas.
* Patient candidate for neo-adjuvant therapy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No